← Back to Treatments
🏅 FDA Orphan Designation

FERRIPROX

DEFERIPRONE

Manufacturer: Chiesi USA, Inc.

Indicated for:
Sickle cell-beta-thalassemia diseaseSickle cell diseaseBeta-thalassemia major
⚠️

Black Box Warning (Boxed Warning)

A Boxed Warning is the FDA's strongest safety warning — it indicates serious or life-threatening risks identified during clinical trials or post-market surveillance. It does not mean the medication is unsafe for all patients; your prescriber weighs these risks against the benefits for your specific situation. Source: FDA-approved prescribing information.

View full prescribing information on DailyMed (NLM) ↗

FDA-Approved Indications (3)

treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes

Population: adult and pediatric patients ≥8 years

treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with sickle cell disease

Population: adult and pediatric patients ≥8 years

treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with other anemias

Population: adult and pediatric patients ≥8 years

Indications & Usage

1 INDICATIONS AND USAGE FERRIPROX Tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. Limitation s of Use • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. FERRIPROX Tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. ( 1 ) Limitation s of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

💙 Support Programs

View all →
FERRIPROX
Chiesi reinforcement _Self-correction:_ The user asked for the primary manufacturer/company that owns the rights. Chiesi is the entity. Final string: Chiesi
Apply ↗
FERRIPROX
Chiesi USA, Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.